No Data
BrainAurora Medical Technology Launches HK$583 Million Hong Kong IPO
Aurora Mobile-B (06681.HK) is expected to be listed on January 8, 2025, with cornerstone investments from Tasly Pharmaceutical Group (Hong Kong) and others.
Gelonghui, on December 30, announced that Aurora Mobile-B (06681.HK) will globally offer approximately 0.181 billion shares, with 18.112 million shares available for sale in Hong Kong and 0.163 billion shares in the international offering, along with a 15% over-allotment option; the subscription period is from December 30, 2024, to January 3, 2025; the offering price will be 3.22 Hong Kong dollars per share, with a minimum trading unit of 1,000 shares. China International Capital Corporation and Shanghai Pudong Development Bank International are the joint sponsors; the shares are expected to start trading on the Stock Exchange on January 8, 2025. The company was established in 2012. The company's business...
Aurora Mobile-B (06681) will start its initial public offering on December 30, having received subscriptions for shares worth 48.5 million USD from four major investors, including Suzhou Ce Yuan and Tasly Pharmaceutical Group (International).
Brain Motion Aurora Mobile-B (06681) plans an initial public offering from December 30, 2024, to January 3, 2025.
Investors in Tasly Pharmaceutical Group (SHSE:600535) Have Unfortunately Lost 10% Over the Last Year
Tasly Pharmaceutical Subsidiary Gets Drug Registration for Muscle Spasms Drug
Tasly Pharmaceutical Group (600535.SH): Subsidiary obtains pharmaceutical registration certificate.
On December 4th, Tasly Pharmaceutical Group (600535.SH) announced that its wholly-owned subsidiary Jiangsu Tasly Pharmaceuticals Co., Ltd. (referred to as "Jiangsu Diyi") received the "Pharmaceutical Registration Certificate" approved and issued by the National Medical Products Administration for Paracetamol Oral Solution. According to the product instructions, Paracetamol Oral Solution is indicated for severe but reversible muscle spasms caused by multiple sclerosis, and may have certain efficacy on spasms caused by infectious, degenerative, traumatic, tumorous, or spinal diseases of unknown etiology.
No Data
